首页> 外文OA文献 >RANDOMIZED PHASE III TRIAL COMPARING EPIRUBICIN/ DOXORUBICIN PLUS DOCETAXEL AND EPIRUBICIN/ DOXORUBICIN PLUS PACLITAXEL AS FIRST LINE TREATMENT IN WOMEN WITH ADVANCED BREAST CANCER

【2h】

RANDOMIZED PHASE III TRIAL COMPARING EPIRUBICIN/ DOXORUBICIN PLUS DOCETAXEL AND EPIRUBICIN/ DOXORUBICIN PLUS PACLITAXEL AS FIRST LINE TREATMENT IN WOMEN WITH ADVANCED BREAST CANCER

机译：随机阶段III试验比较EPIRUBICIN / DOXORUBICIN PLUS DOCETAXEL和EPIRUBICIN / DOXORUBICIN PLUS PACLITAXEL作为晚期乳腺癌妇女的第一线治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Seema Devi; Yogesh Kumar Sharma; Dilip Shah;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. [J] . Mavroudis D, Papakotoulas P, Ardavanis Annals of oncology: official journal of the European Society for Medical Oncology . 2010,第1期

机译：比较多西他赛加表柔比星与多西他赛加卡培他滨作为晚期乳腺癌妇女的一线治疗的随机III期试验。
2. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial [J] . Schneeweiss Andreas, Moebus Volker, Tesch Hans, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：激烈剂量 - 致密的Epirubicin，紫杉醇，环磷酰胺与每周紫杉醇，脂质体Doxorubicin（加上三重阴性乳腺癌中的Carboplatin）用于Neoadjuvant治疗高危早期乳腺癌（Geparocto-GBG 84）：随机期III试验
3. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatmentn in women with advanced breast cancer [J] . Annals of Oncology . 2010,第1期

机译：比较多西紫杉醇联合表柔比星与多西紫杉醇联合卡培他滨作为一线治疗晚期乳腺癌妇女的Ⅲ期随机试验
4. Epirubicin hydrochloride loaded poly (butylcyanoacrylate) nanoparticles: Formulation optimization, characterization and in-vitro evaluation in human breast cancer cell lines [C] . Prudhviraju Dantuluri, Neha Shah, M. R. Sunil Kumar, Nanotechnology 2009 : Technical proceedings . 2009

机译：盐酸表柔比星负载的聚（氰基丙烯酸丁酯）纳米颗粒：在人类乳腺癌细胞系中的配方优化，表征和体外评估
5. Cost effectiveness of liposomal doxorubicin versus paclitaxel for the treatment of advanced AIDS-related Kaposis Sarcoma. [D] . Raimundo, Karina Pupio. 2011

机译：脂质体阿霉素与紫杉醇在治疗晚期艾滋病相关的卡波西斯肉瘤中的成本效益。
6. Doxorubicin vs epirubicin report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. [O] . M. Bontenbal, M. Andersson, J. Wildiers, 1998

机译：阿霉素vs表柔比星晚期乳腺癌的二线随机II / III期研究报告。 EORTC乳腺癌合作小组。
7. A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study [O] . Patrizia Vici, Giuseppe Colucci, Francesco Giotta, 2011

机译：表柔比星/长春瑞滨与聚乙二醇化脂质体阿霉素/长春瑞滨为晚期乳腺癌的一线治疗的多中心前瞻性II期随机试验。 GOIM研究

RANDOMIZED PHASE III TRIAL COMPARING EPIRUBICIN/ DOXORUBICIN PLUS DOCETAXEL AND EPIRUBICIN/ DOXORUBICIN PLUS PACLITAXEL AS FIRST LINE TREATMENT IN WOMEN WITH ADVANCED BREAST CANCER

著录项

引文网络

相似文献

相关主题

期刊订阅